Cargando…

Identification of Targets from LRRK2 Rescue Phenotypes

Parkinson’s disease (PD) is an age-dependent neurodegenerative condition. Leucine-rich repeat kinase 2 (LRRK2) mutations are the most frequent cause of sporadic and autosomal dominant PD. The exact role of LRRK2 protective variants (R1398H, N551K) together with a pathogenic mutant (G2019S) in aging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toh, Joanne, Chua, Ling Ling, Ho, Patrick, Sandanaraj, Edwin, Tang, Carol, Wang, Hongyan, Tan, Eng King
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824855/ https://www.ncbi.nlm.nih.gov/pubmed/33466414 http://dx.doi.org/10.3390/cells10010076

Ejemplares similares

Chetomin rescues pathogenic phenotype of LRRK2 mutation in drosophila
por: Chua, Ling Ling, et al.
Publicado: (2020)

MAP1B rescues LRRK2 mutant-mediated cytotoxicity
por: Chan, Sharon L, et al.
Publicado: (2014)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Evaluating LRRK2 Genetic Variants with Unclear Pathogenicity
por: Refai, Fathima Shaffra, et al.
Publicado: (2015)

Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2
por: Angeles, Dario C., et al.
Publicado: (2016)

Non-Motor and Motor Features in LRRK2 Transgenic Mice
por: Bichler, Zoë, et al.
Publicado: (2013)

Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population
por: Yu, Wen-Juan, et al.
Publicado: (2015)

Patterns of Linkage Disequilibrium of LRRK2 across Different Races: Implications for Genetic Association Studies
por: Li, Huihua, et al.
Publicado: (2013)

Case-control analysis of LRRK2 protective variants in Essential Tremor
por: Ng, Adeline S. L., et al.
Publicado: (2018)

Lrrk2 R1628P variant is a risk factor for essential tremor
por: Chao, Yin Xia, et al.
Publicado: (2015)

LRRK2 A419V Is Not Associated with Parkinson's Disease in Different Chinese Populations
por: Wu, Yih Ru, et al.
Publicado: (2012)

A STAT3-based gene signature stratifies glioma patients for targeted therapy
por: Tan, Melanie Si Yan, et al.
Publicado: (2019)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation
por: Chang, Kuo-Hsuan, et al.
Publicado: (2021)

Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease
por: Deng, Xiao, et al.
Publicado: (2020)

Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype
por: Rassu, Mauro, et al.
Publicado: (2019)

Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals
por: Zheng, Yifan, et al.
Publicado: (2015)

Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
por: Singh, Francois, et al.
Publicado: (2021)

The LRRK2 signalling system
por: Price, Alice, et al.
Publicado: (2018)

In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila
por: Wang, Hua-shan, et al.
Publicado: (2014)

Differential LRRK2 signalling and gene expression in WT-LRRK2 and G2019S-LRRK2 mouse microglia treated with zymosan and MLi2
por: Nazish, Iqra, et al.
Publicado: (2023)

LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson’s disease: a review
por: Chen, Meng-Ling, et al.
Publicado: (2018)

Dynamic and redundant regulation of LRRK2 and LRRK1 expression
por: Biskup, Saskia, et al.
Publicado: (2007)

‘Up with the LRRK’: a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement
por: Eyers, Patrick A.
Publicado: (2016)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
por: Goveas, Liesel, et al.
Publicado: (2021)

Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

The emerging role of LRRK2 in tauopathies
por: Herbst, Susanne, et al.
Publicado: (2022)

LRRK2: Cause, Risk, and Mechanism
por: Paisán-Ruiz, Coro, et al.
Publicado: (2013)

Identification of peptides interfering with the LRRK2/PP1 interaction
por: Dong, Chang Zhi, et al.
Publicado: (2020)

Computational analysis of the LRRK2 interactome
por: Manzoni, Claudia, et al.
Publicado: (2015)

Capturing the domain crosstalk in full length LRRK2 and LRRK2(RCKW)
por: Störmer, Eliza, et al.
Publicado: (2023)

Assaying the Kinase Activity of LRRK2 in vitro
por: Lewis, Patrick A.
Publicado: (2012)

Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations
por: Godena, Vinay K., et al.
Publicado: (2014)

A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2
por: Kuhlmann, Naila, et al.
Publicado: (2020)

Designing antibodies against LRRK2-targeted tau epitopes
por: Hamm, Matthew, et al.
Publicado: (2018)

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
por: Wojewska, Dominika Natalia, et al.
Publicado: (2021)

LRRK2 and Parkinson's disease: from genetics to targeted therapy
por: Sosero, Yuri L., et al.
Publicado: (2023)

Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
por: De Wit, T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hh206avn62esagoggf49hlm0ee